News ArticleKrishna Institute of Medical Sciences Reports 41.3% Revenue Growth to INR 1,363 Crore in Q2 FY27
EBITDA rises 34% year-on-year to INR 279 crore; Q2 PAT reaches INR 76 crore amid operational expansion
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) announced robust financial results for Q2 FY27, posting a 41.3% year-on-year increase in total income to INR 1,363 crore. The company achieved an EBITDA of INR 279 crore and a profit after tax of INR 76 crore, supported by operational growth in patient volumes and average revenue per patient metrics.
Krishna Institute of Medical Sciences Limited
General / Other
Krishna Institute of Medical Sciences Limited (KIMS Hospitals) reported strong consolidated financial results for the second quarter ended September 30, 2026, with total income increasing by 41.3% year-on-year to INR 1,363 crore and profitability metrics showing significant improvement.
The company recorded an EBITDA of INR 279 crore for Q2 FY27, marking a 34.0% increase versus the same quarter last year, with an EBITDA margin of 20.5%. Profit after tax (PAT) stood at INR 76 crore, up from INR 37 crore in Q2 FY26.
Operationally, KIMS reported inpatient volumes of 81,668 and outpatient volumes of 7,31,010 in the quarter, showing year-on-year increases of 27.0% and 23.3% respectively. Average revenue per occupied bed (ARPOB) rose by 14.9% to INR 48,277, and average revenue per patient (ARPP) increased by 9.9% to INR 1,65,577.
The company also highlighted notable clinical achievements during the quarter, including successful high-complexity surgeries and critical care interventions across its Secunderabad and Kondapur facilities.
Cash and cash equivalents were reported at INR 420 crore as of September 30, 2026.
KIMS continues to leverage advanced medical technologies, with KIMS Secunderabad reaching 300 robotic surgeries executed on the Da Vinci XI system, making it a leading robotic surgery program in Telangana and India.
Highlights
- Total revenue of INR 1,363 crore in Q2 FY27, a 41.3% increase year-on-year.
- EBITDA increased 34.0% year-on-year to INR 279 crore with a 20.5% margin.
- Net profit (PAT) rose to INR 76 crore from INR 37 crore in Q2 FY26.
- Inpatient and outpatient volumes grew by 27.0% and 23.3%, respectively.
- ARPOB and ARPP grew 14.9% and 9.9% year-on-year, respectively.
- Cash and cash equivalents stood at INR 420 crore as of September 30, 2026.
Key Data Snapshot
What happened
- Krishna Institute of Medical Sciences Limited reported consolidated total income of INR 1,363 crore for Q2 FY27, showing a 41.3% year-on-year increase.
- EBITDA for the quarter increased by 34.0% year-on-year to INR 279 crore with a margin of 20.5%.
- Profit after tax rose to INR 76 crore in Q2 FY27 from INR 37 crore in Q2 FY26.
- Operational volumes grew with inpatient numbers up 27.0% and outpatient numbers up 23.3% year-on-year.
- Average revenue per occupied bed and per patient increased 14.9% and 9.9%, respectively.
- Cash and cash equivalents reached INR 420 crore as of September 30, 2026.
Key details
- Revenue from operations was INR 1,344 crore in Q2 FY27, up 39.9% year-on-year and 14.0% quarter-on-quarter.
- EBITDA excluding other income and INDAS adjustments was INR 232 crore, up 17.9% year-on-year.
- Consolidated earnings per share for the quarter were INR 1.8, an 8.5% increase year-on-year.
- The company excluded exceptional and other income gains in its EBITDA metrics for precise operational performance assessment.
Operational performance
- Inpatient and outpatient volumes increased to 81,668 and 7,31,010 respectively in Q2 FY27 compared to the prior year.
- Average revenue per occupied bed (ARPOB) rose by 14.9% to INR 48,277 compared to Q2 FY26.
- Average revenue per patient (ARPP) grew 9.9% year-on-year to INR 1,65,577.
- KIMS Secunderabad achieved 300 robotic surgeries on the Da Vinci XI system, marking a leading robotic surgery program in Telangana and India.
Business impact
- The company reported multiple significant clinical interventions during Q2 FY27, including complex surgeries and critical care successes across its hospital locations.
- Examples include a successful ECMO-supported respiratory distress treatment, rare intestinal cancer management with transplanted kidney preservation, and complex cardiac and gastroenterological surgeries.
Regulatory and governance context
- Results were approved by the Board of Directors and the press release was submitted to Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in accordance with SEBI (LODR) Regulations, 2015.
- The filing date for the results was November 4, 2026.
Highlights
- Total revenue of INR 1,363 crore in Q2 FY27, a 41.3% increase year-on-year.
- EBITDA increased 34.0% year-on-year to INR 279 crore with a 20.5% margin.
- Net profit (PAT) rose to INR 76 crore from INR 37 crore in Q2 FY26.
- Inpatient and outpatient volumes grew by 27.0% and 23.3%, respectively.
- ARPOB and ARPP grew 14.9% and 9.9% year-on-year, respectively.
- Cash and cash equivalents stood at INR 420 crore as of September 30, 2026.
Disclosures
- SEBI (LODR) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Tube Investments of India Posts Rs. 188.16 Crore Net Profit in Q2 FY 2026-27, Approves Rs. 83 Crore Project to Expand CRSS Capacity
Tube Investments of India Limited released its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, reporting a net profit after tax of Rs. 188.16 crore for the quarter. Additionally, the company’s Board approved a capital expenditure of up to Rs. 83 crore to expand capacity in its Cold Rolled Steel Strips manufacturing at Avadi, targeting FY 2027-28 completion.
Read Full Story
Authum Investment & Infrastructure Ltd Announces Unaudited Financial Results for Q2 and H1 Ending September 30, 2026
Authum Investment & Infrastructure Ltd has released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, in compliance with SEBI Listing Regulations.
Read Full Story
Radico Khaitan Limited's Registrar and Share Transfer Agent Shifts Corporate Office to New Hyderabad Location from December 1, 2026
Radico Khaitan Limited has notified investors that its Registrar and Share Transfer Agent, KFin Technologies Limited, will relocate its corporate office in Hyderabad effective December 1, 2026, to a new address within Serilingampally Mandal, Ranga Reddy district.
Read Full Story
